Abstract
Inflammatory bowel disease (IBD) patients are at increased risk of colorectal cancer (CRC)1. Tumor initiating events in colitis-associated cancers (CACs) differ significantly from sporadic CRC2. In CACs, hyperactivity of wnt/beta-catenin signaling typically occur without adenomatous polyposis coli gene mutations commonly seen in sporadic colon cancers. This suggests distinct mechanisms cause dysregulation of wnt signaling in CACs. A20 (TNFAIP3) is a ubiquitin-editing enzyme, linked to IBD, with roles in dampening inflammation3. We found that A20 is a tumor suppressor in the murine colon directly inhibiting beta-catenin signaling4. We now report regulation of wnt signaling by A20 depends on interaction with receptor interacting protein kinase 4 (RIPK4). Interestingly, A20’s function downstream of inflammatory signaling depends upon the closely related proteins RIPK1 and RIPK2 suggesting a conserved interaction between A20 and this family of proteins. Using a mammalian yeast-2-hybrid system we found A20 and RIPK4 interact (Fig. 1A). This association was confirmed via immunoprecipitation using endogenous proteins and was dependent upon wnt stimulation (Fig. 1B). Using a beta-catenin luciferase reporter assay, we showed siRNA knockdown of RIPK4 partially abrogates enhanced wnt signaling in absence of A20 (Fig. 1C), suggesting A20 negatively regulates wnt signaling via RIPK4. Mechanistically, we found A20 normally supports K48-linked ubiquitination of RIPK4 (Fig. 1D). We then determined whether A20 plays a role in regulating CACs with the AOM-DSS model of CAC in mice with a targeted deletion of A20 in the intestinal epithelium. Preliminary data suggests A20FL/FL Villin-Cre mice treated with AOM-DSS develop larger tumors than control mice (Figs. 2A,2B). Overall, we propose that A20 restricts CACs by inhibiting the activity of RIPK4. 1. Gut. 2001;48(4):526-35. 2. Cancer Res. 1995;55(10):2035-38. 3. Nat. Rev. Immunol. 2012;12:774-85. 4. PLoS One. 2013;8(5):e62223.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.